MedTrace Logo

A Trial In Diabetic Patients To Assess Effect Of CE-326,597 On Glucose Control And Body Weight

NCT00542009 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 252

Last updated 2012-11-07

No results posted yet for this study

Summary

Study of whether the investigational drug CE-326,597 improves glucose control and results in body weight loss in patients with type 2 diabetes

Conditions

Interventions

DRUG

CE-326,597 100 mg QD

Administered orally, once daily with morning meal for duration of trial (84 days).

DRUG

CE-326,597 50 mg QD

Administered orally, once daily with morning meal for duration of trial (84 days).

DRUG

CE-326,597 25 mg QD

Administered orally, once daily with morning meal for duration of trial (84 days).

DRUG

Placebo

Placebo to match CE-326,597 tablets to be administered orally, once daily with morning meal for duration of trial (84 days).

DRUG

CE-326,597 5mg QD

Administered orally, once daily with morning meal for duration of trial (84 days).

Sponsors & Collaborators

Principal Investigators

  • Pfizer CT.gov Call Center · Pfizer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-12-31
Primary Completion
2008-11-30
Completion
2008-11-30

Countries

  • United States
  • Bulgaria
  • Canada
  • India
  • Mexico
  • Puerto Rico
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00542009 on ClinicalTrials.gov